The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Party season approaches; but first, conferences.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
First-in-human trial initiations reveal four KRAS assets.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
Patients' expression of CEACAM5 might hold the key to activity after all.
It’s back to school for biotech, with a packed conference schedule.